TocilizumabV1, Pmc, Checkpoint, indexHead, PmcKwd.i

Index : PmcKwd.i

Les termes de plus forte occurence

163	rheumatoid arthritis
105	Rheumatoid arthritis
70	COVID-19
56	inflammation
51	tocilizumab
43	Tocilizumab
42	Treatment
41	SARS-CoV-2
34	Inflammation
33	Rheumatoid Arthritis
32	DMARDs (biologic)
28	IL-6
26	immunotherapy
25	treatment
24	cytokines
23	interleukin-6
23	biologics
20	Methotrexate
19	Immunotherapy
17	systemic sclerosis
17	methotrexate
17	epidemiology
17	biomarkers
17	Juvenile idiopathic arthritis
17	Interleukin-6
16	systemic lupus erythematosus
16	anakinra
16	Cytokines
16	Coronavirus
16	Abatacept
15	psoriatic arthritis
14	interstitial lung disease
14	autoimmunity
14	arthritis
14	Biologics
13	chimeric antigen receptor
13	Anti-TNF
12	immunosuppression
12	giant cell arteritis
12	Systemic sclerosis
12	STAT3
12	Cancer
11	therapy
11	systemic juvenile idiopathic arthritis
11	juvenile idiopathic arthritis
11	disease activity
11	cytokine
11	autoimmune diseases
11	Biomarkers
10	canakinumab
10	Takayasu arteritis
10	T cells
10	Outcomes research
10	Immunology
10	Diagnosis
10	DMARDs
9	vasculitis
9	scleroderma
9	monoclonal antibodies
9	coronavirus
9	cancer
9	Epidemiology
9	Disease activity
9	Disease Activity
9	Cardiovascular disease
9	Biomarker
9	B cells
8	tumor microenvironment
8	rituximab
8	rheumatology
8	precision medicine
8	multiple sclerosis
8	macrophages
8	inflammatory bowel disease
8	disease-modifying antirheumatic drugs
8	cytokine release syndrome
8	ankylosing spondylitis
8	abatacept
8	Uveitis
8	TAFRO syndrome
8	T cell
8	Rituximab
8	Pathogenesis
8	Oncology
8	Infection
8	Hydroxychloroquine
8	DMARDs (synthetic)
8	Autoimmunity
8	Arthritis
7	ulcerative colitis
7	tofacitinib
7	safety
7	rheumatic diseases
7	primary immunodeficiency
7	osteoporosis
7	management
7	innate immunity
7	immunomodulation
7	immune checkpoint inhibitors
7	fibrosis
7	dmards (biologic)
7	corticosteroids
7	breast cancer
7	autophagy
7	atherosclerosis
7	anti-TNF
7	Giant cell arteritis
7	Etanercept
7	DAS28
7	Covid-19
6	transplantation
6	targeted therapy
6	pharmacokinetics
6	neutrophils
6	monoclonal antibody
6	lymphoma
6	interleukin‐6
6	interleukin 6
6	infliximab
6	infection
6	immunology
6	immunogenicity
6	hemophagocytic lymphohistiocytosis
6	efficacy
6	clinical trials
6	cardiovascular disease
6	autoimmune disease
6	Vasculitis
6	Th17
6	Sepsis
6	Sarilumab
6	Safety
6	SLE
6	Rheumatic diseases
6	Remission
6	Kidney transplantation
6	Interstitial lung disease
6	Infections
6	Early Rheumatoid Arthritis
6	Cytokine
6	Cytokine storm
6	Cytokine release syndrome
6	Children
6	CD19
6	C-reactive protein
6	Biological therapy
6	Adult-onset Still’s disease
5	systematic review
5	regulatory T cells
5	randomized controlled trial
5	pro-inflammatory cytokines
5	pregnancy
5	personalized medicine
5	pathogenesis
5	ovarian cancer
5	obesity
5	metabolism
5	macrophage activation syndrome
5	interleukins
5	infections
5	hydroxychloroquine
5	gp130
5	gene therapy
5	diabetes
5	depression
5	collagen-induced arthritis
5	biologic therapies
5	apoptosis
5	adverse events
5	Ultrasonography
5	Transplantation
5	Therapy
5	Systemic lupus erythematosus
5	Sjögren’s syndrome
5	Prognosis
5	Outcome
5	Molecular biology
5	Malignancy
5	Macrophage activation syndrome
5	Lymphoma
5	Juvenile Idiopathic Arthritis
5	IL-1
5	Hematology
5	HIV
5	GM-CSF
5	Clinical trial
5	Chloroquine
5	Chimeric antigen receptor
5	Castleman disease
5	Case report
5	Cancer immunotherapy
5	Biologic agents
5	Atherosclerosis
5	Adverse events
5	2019-nCoV
4	tuberculosis
4	tolerance
4	schizophrenia
4	review
4	remdesivir
4	polymyalgia rheumatica
4	oxidative stress
4	osteoarthritis
4	neuromyelitis optica
4	neuroinflammation
4	myocarditis
4	multiple myeloma
4	monocytes
4	meta-analysis
4	macrophage
4	lung cancer
4	interleukin
4	innovative biotechnologies
4	hepatitis B virus
4	glucocorticoids
4	glioblastoma
4	genetics
4	diagnosis
4	chloroquine
4	chemotherapy
4	chemokines
4	cardiovascular risk
4	cardiovascular diseases
4	biological therapy
4	biologic therapy
4	autoinflammatory diseases
4	allergy
4	adult-onset Still’s disease
4	adenosine
4	Vaccination
4	Tumor microenvironment
4	Translational research
4	Toxicity
4	Therapeutics
4	Targeted therapy
4	TNF
4	TNF-α
4	SARS
4	Rheumatology
4	Review
4	Remdesivir
4	Psoriasis
4	Pregnancy
4	Pneumonia
4	Pharmacokinetics
4	Patient-reported outcomes
4	PD-1
4	Management
4	Interleukin-1
4	Intensive care
4	Immunosuppression
4	Immune-related adverse events
4	Immune checkpoint inhibitors
4	IL-17
4	Hemophagocytic lymphohistiocytosis
4	HLH
4	Gene expression
4	Drug development
4	Diabetes
4	DMARD
4	Crohn’s disease
4	Complications
4	Cell death and immune response
4	CAR-T
4	CAR T cells
4	Biologic
4	Behçet’s disease
4	Baricitinib
4	Anakinra
4	Amyotrophic lateral sclerosis
4	ANCA
3	免疫检查点抑制剂
3	vascular endothelial growth factor
3	vaccine
3	uveitis
3	tisagenlecleucel
3	thrombocytopenia
3	systemic vasculitis
3	spondyloarthritis
3	sarilumab
3	sarcoidosis
3	rheumatic disease
3	resistance
3	relapsing polychondritis
3	registry
3	psychoneuroimmunology
3	psychology
3	prognosis
3	population pharmacokinetics
3	polarization
3	pharmacovigilance
3	pembrolizumab
3	pediatric
3	pain
3	outcome
3	osteoclasts
3	neuromyelitis optica spectrum disorders
3	network meta-analysis
3	miRNAs
3	miRNA
3	macular edema
3	leukemia
3	kidney transplantation
3	interleukin-1β
3	interleukin-1
3	interleukin-17
3	immune-related adverse events
3	immune dysregulation
3	immune checkpoint inhibitor
3	idiopathic
3	hepcidin
3	hematopoietic stem cell transplantation
3	glucocorticoid
3	fibroblast-like synoviocytes
3	fever
3	fatigue
3	exercise
3	elderly
3	early rheumatoid arthritis
3	dmards (synthetic)
3	dermatomyositis
3	denosumab
3	dendritic cells
3	cytokine storm
3	cyclophosphamide
3	complications
3	clinical management
3	cancer immunotherapy
3	bronchiectasis
3	bone metastasis
3	biotherapy
3	biotherapies
3	biosimilars
3	biological agents
3	biologic drugs
3	biologic DMARDs
3	belimumab
3	axial spondyloarthritis
3	autoinflammatory
3	autoimmune encephalitis
3	autoantibodies
3	antibodies
3	acute respiratory distress syndrome
3	acute lymphoblastic leukemia
3	acute kidney injury
3	Wnt signaling
3	WHO, World Health Organization
3	Tregs
3	Tofacitinib
3	Taiwan
3	TNFα
3	TNF inhibitors
3	Systemic juvenile idiopathic arthritis
3	Systematic review
3	Synovitis
3	Smoking
3	Sarcoidosis
3	STAT5
3	SARS-CoV
3	Risk factors
3	Response
3	Respiratory
3	Relapse
3	Registry
3	Prevalence
3	Polymyalgia rheumatica
3	Polymyalgia Rheumatica
3	Pneumonitis
3	Personalized medicine
3	Patient perspective
3	Neutropenia
3	NSCLC
3	NF-κB
3	Multiple myeloma
3	Monotherapy
3	Monoclonal antibody
3	Molecular medicine
3	Microglia
3	Meta-analysis
3	Macrophages
3	Janus kinase
3	JAK
3	JAK, Janus kinase
3	Interleukins
3	Interleukin 6
3	Infliximab
3	Inflammatory diseases
3	Immunosuppressive agents
3	Immune-related adverse event
3	Immune response
3	Immune checkpoint inhibitor
3	IL‐6
3	IL-6R
3	Human
3	Hepatitis B virus
3	Heart failure
3	GVHD
3	Fatigue
3	FDA, Food and Drug Administration
3	Experimental models of disease
3	Epigenetics
3	Eosinophilic fasciitis
3	Diagnostic markers
3	Dermatomyositis
3	DNA methylation
3	Cyclophosphamide
3	Corticosteroids
3	Coronavirus disease 2019
3	Chemotherapy
3	Checkpoint inhibitors
3	Cardiovascular Disease
3	CAR T-cell therapy
3	Breast cancer
3	Blau syndrome
3	Biologicals
3	Biological agents
3	B cell
3	Autophagy
3	Autoimmune disease
3	Arthritis, rheumatoid
3	Apoptosis
3	Ankylosing Spondylitis
3	Adverse effects
3	Adult
3	Acute respiratory distress syndrome
3	ARDS
3	ADAM17
2	免疫相关不良反应
2	viral hepatitis
2	vaccination
2	upadacitinib
2	unmet needs
2	tumour microenvironment
2	tumor
2	tumor-associated macrophages
2	tumor necrosis factor inhibitors
2	treatment costs
2	treat to target
2	toxicity
2	therapeutics
2	therapeutic drug monitoring
2	tacrolimus
2	systemic onset juvenile idiopathic arthritis
2	systemic inflammation
2	synovium
2	synovitis
2	synovial fluid
2	symposium
2	stress
2	statin
2	sirolimus
2	signal detection
2	serositis
2	screening
2	risk factors
2	rheumatoid
2	rheumatoid factor
2	renal cell carcinoma
2	remission
2	regulation
2	recommendations
2	reactivation
2	pulmonary hypertension
2	pulmonary arterial hypertension
2	psychiatry
2	psoriasis
2	primary immunodeficiency diseases (PID)
2	primary immunodeficiencies
2	preventive medicine
2	prevention
2	predictive factors
2	prediction
2	positron emission tomography
2	polymyositis
2	polymorphism
2	podocyte
2	pleuropericarditis
2	physical activity
2	pharmacology
2	pharmacodynamics
2	periodontitis
2	periodontal disease
2	pediatrics
2	patients
2	patient-reported outcomes
2	pathophysiology
2	pathology
2	pandemic
2	overall survival
2	outcomes
2	outcomes research
2	outcome measures
2	outbreak
2	osteoclast
2	organizing pneumonia
2	optic neuritis
2	oncoviruses
2	oncology
2	novel coronavirus
2	nivolumab

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/explor/Tocilizumab.storage/TocilizumabV1/Data/Pmc/Checkpoint/PmcKwd.i.hfd| SxmlCut idx/l | grep ...

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

	Serveur d'exploration Tocilizumab - Checkpoint (Pmc) Index « PmcKwd.i » - tête de navigation
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Tocilizumab - Checkpoint (Pmc)Index « PmcKwd.i » - tête de navigation

Index : PmcKwd.i

Les termes de plus forte occurence

Manipulations en shell (Unix/Dilib)

Serveur d'exploration Tocilizumab - Checkpoint (Pmc)

Index « PmcKwd.i » - tête de navigation